Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indravadan Patel

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Current Medical Research and Opinion|November 6, 2025
Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicityLisa Dwyer Orr, Pratyusha Vadagam, Julie Vanderpoel, et al.
Phlebology|August 8, 2020
Imaging findings of pelvic venous insufficiency in patients with postural orthostatic tachycardia syndromeMartha-Gracia Knuttinen, Kenneth S Zurcher, Neal Khurana, et al.
American Heart Journal|October 12, 2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.
Obesity Surgery|January 10, 2018
Does Sleeve Shape Make a Difference in Outcomes?Adel Alhaj Saleh, Michal R Janik, Rami R Mustafa, et al.
Lancet (London, England)|March 15, 2015
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|December 5, 2013
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48Deepak K Gupta, Amil M Shah, Robert P Giugliano, et al.
Thrombosis and Haemostasis|March 9, 2012
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillationDaniel E Salazar, Jeanne Mendell, Helen Kastrissios, et al.
Current Medicinal Chemistry|December 23, 2021
Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth ReviewTarun Kumar Upadhyay, Mohammed Irfan Ali, Fahad Khan, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2025
The oncogene SLC35F2 is a high-specificity transporter for the micronutrients queuine and queuosineLyubomyr Burtnyak, Yifeng Yuan, Erwina Stojek, et al.
The New England Journal of Medicine|November 21, 2013
Edoxaban versus warfarin in patients with atrial fibrillationRobert P Giugliano, Christian T Ruff, Eugene Braunwald, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Current Medical Research and Opinion|November 6, 2025
Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicityLisa Dwyer Orr, Pratyusha Vadagam, Julie Vanderpoel, et al.
Phlebology|August 8, 2020
Imaging findings of pelvic venous insufficiency in patients with postural orthostatic tachycardia syndromeMartha-Gracia Knuttinen, Kenneth S Zurcher, Neal Khurana, et al.
American Heart Journal|October 12, 2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.
Obesity Surgery|January 10, 2018
Does Sleeve Shape Make a Difference in Outcomes?Adel Alhaj Saleh, Michal R Janik, Rami R Mustafa, et al.
Lancet (London, England)|March 15, 2015
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|December 5, 2013
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48Deepak K Gupta, Amil M Shah, Robert P Giugliano, et al.
Thrombosis and Haemostasis|March 9, 2012
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillationDaniel E Salazar, Jeanne Mendell, Helen Kastrissios, et al.
Current Medicinal Chemistry|December 23, 2021
Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth ReviewTarun Kumar Upadhyay, Mohammed Irfan Ali, Fahad Khan, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2025
The oncogene SLC35F2 is a high-specificity transporter for the micronutrients queuine and queuosineLyubomyr Burtnyak, Yifeng Yuan, Erwina Stojek, et al.
The New England Journal of Medicine|November 21, 2013
Edoxaban versus warfarin in patients with atrial fibrillationRobert P Giugliano, Christian T Ruff, Eugene Braunwald, et al.
Pageof 5